Molecular Determinants for Enzalutamide-induced Transcription in Prostate Cancer

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2019 Sep 11

PMID 31501863

Citations 18

Authors

Fuwen Yuan

William Hankey

Dayong Wu

Hongyan Wang

Jason Somarelli

Andrew J Armstrong

Jiaoti Huang

Zhong Chen

Qianben Wang

Affiliations

Soon will be listed here.

Abstract

Enzalutamide, a second-generation androgen receptor (AR) antagonist, has demonstrated clinical benefit in men with prostate cancer. However, it only provides a temporary response and modest increase in survival, indicating a rapid evolution of resistance. Previous studies suggest that enzalutamide may function as a partial transcriptional agonist, but the underlying mechanisms for enzalutamide-induced transcription remain poorly understood. Here, we show that enzalutamide stimulates expression of a novel subset of genes distinct from androgen-responsive genes. Treatment of prostate cancer cells with enzalutamide enhances recruitment of pioneer factor GATA2, AR, Mediator subunits MED1 and MED14, and RNA Pol II to regulatory elements of enzalutamide-responsive genes. Mechanistically, GATA2 globally directs enzalutamide-induced transcription by facilitating AR, Mediator and Pol II loading to enzalutamide-responsive gene loci. Importantly, the GATA2 inhibitor K7174 inhibits enzalutamide-induced transcription by decreasing binding of the GATA2/AR/Mediator/Pol II transcriptional complex, contributing to sensitization of prostate cancer cells to enzalutamide treatment. Our findings provide mechanistic insight into the future combination of GATA2 inhibitors and enzalutamide for improved AR-targeted therapy.

Citing Articles

Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk.

Hiltunen J, Helminen L, Paakinaho V Front Endocrinol (Lausanne). 2024; 15:1437179.

PMID: 39027480 PMC: 11254642. DOI: 10.3389/fendo.2024.1437179.

Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.

Gao H, Wei L, Indulkar S, Nguyen T, Liu D, Ho M Breast Cancer Res. 2024; 26(1):111.

PMID: 38965614 PMC: 11225427. DOI: 10.1186/s13058-024-01861-2.

A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy.

Subramanian A, Zhang M, Sharifi M, Moreno-Rodriguez T, Feng E, Rydzewski N bioRxiv. 2024; .

PMID: 38895460 PMC: 11185575. DOI: 10.1101/2024.06.02.595931.

SIX2 promotes cell plasticity via Wnt/β-catenin signalling in androgen receptor independent prostate cancer.

Leppanen N, Kaljunen H, Takala E, Kaarijarvi R, Makinen P, Yla-Herttuala S Nucleic Acids Res. 2024; 52(10):5610-5623.

PMID: 38554106 PMC: 11162805. DOI: 10.1093/nar/gkae206.

Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.

Helminen L, Huttunen J, Tulonen M, Aaltonen N, Niskanen E, Palvimo J Nucleic Acids Res. 2023; 52(2):625-642.

PMID: 38015476 PMC: 10810216. DOI: 10.1093/nar/gkad1126.

References

Knudsen K, Penning T . Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010; 21(5):315-24. PMC: 2862880. DOI: 10.1016/j.tem.2010.01.002. View

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky M, Domingo-Domenech J . The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol. 2016; 14(1):38-48. PMC: 5489122. DOI: 10.1038/nrurol.2016.225. View

Greasley R, Khabazhaitajer M, Rosario D . A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res. 2015; 7:153-64. PMC: 4472073. DOI: 10.2147/CMAR.S50585. View

Gronemeyer H, Gustafsson J, Laudet V . Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov. 2004; 3(11):950-64. DOI: 10.1038/nrd1551. View

Leibowitz-Amit R, Joshua A . Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol. 2013; 19(Suppl 3):S22-31. PMC: 3553559. DOI: 10.3747/co.19.1281. View

Boyes J, Byfield P, Nakatani Y, Ogryzko V . Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 1998; 396(6711):594-8. DOI: 10.1038/25166. View

Zalachoras I, Houtman R, Atucha E, Devos R, Tijssen A, Hu P . Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc Natl Acad Sci U S A. 2013; 110(19):7910-5. PMC: 3651427. DOI: 10.1073/pnas.1219411110. View

Wang Q, Carroll J, Brown M . Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell. 2005; 19(5):631-42. DOI: 10.1016/j.molcel.2005.07.018. View

10.

Heinlein C, Chang C . Androgen receptor in prostate cancer. Endocr Rev. 2004; 25(2):276-308. DOI: 10.1210/er.2002-0032. View

11.

Kumar R, McEwan I . Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev. 2012; 33(2):271-99. PMC: 3596562. DOI: 10.1210/er.2011-1033. View

12.

Wang Q, Sharma D, Ren Y, Fondell J . A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem. 2002; 277(45):42852-8. DOI: 10.1074/jbc.M206061200. View

13.

Mangelsdorf D, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K . The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6):835-9. PMC: 6159888. DOI: 10.1016/0092-8674(95)90199-x. View

14.

Chen Z, Lan X, Thomas-Ahner J, Wu D, Liu X, Ye Z . Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 2014; 34(4):502-16. PMC: 4331004. DOI: 10.15252/embj.201490306. View

15.

Alessandrini F, Pezze L, Ciribilli Y . LAMPs: Shedding light on cancer biology. Semin Oncol. 2018; 44(4):239-253. DOI: 10.1053/j.seminoncol.2017.10.013. View

16.

Jeronimo C, Robert F . The Mediator Complex: At the Nexus of RNA Polymerase II Transcription. Trends Cell Biol. 2017; 27(10):765-783. DOI: 10.1016/j.tcb.2017.07.001. View

17.

Calo E, Wysocka J . Modification of enhancer chromatin: what, how, and why?. Mol Cell. 2013; 49(5):825-37. PMC: 3857148. DOI: 10.1016/j.molcel.2013.01.038. View

18.

Shah N, Wang P, Wongvipat J, Karthaus W, Abida W, Armenia J . Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017; 6. PMC: 5593504. DOI: 10.7554/eLife.27861. View

19.

Gibbons J, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt J, Beddo V . Clinical Pharmacokinetic Studies of Enzalutamide. Clin Pharmacokinet. 2015; 54(10):1043-55. PMC: 4580721. DOI: 10.1007/s40262-015-0271-5. View

20.

Cirillo L, Lin F, Cuesta I, Friedman D, Jarnik M, Zaret K . Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002; 9(2):279-89. DOI: 10.1016/s1097-2765(02)00459-8. View